IP Library Granted Patent US 6,872,390
Granted Patent B2
US 6,872,390 · App. 10/155,020 · Granted Mar 29, 2005

Local anesthetic methods and kits

Assignee: Novalar Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,872,390
App. No.
10/155,020
Granted
Mar 29, 2005
Kind
B2
Abstract

Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.

Claims (12)

1. A solution comprising phentolamine mesylate at a concentration of from about 0.001 mg/ml to about 0.25 mg/ml, wherein said solution is effective to reverse anesthesia in an animal caused by previous administration of an anesthetic agent and an alpha adrenergic receptor agonist, said solution being present in a container that fits into a standard dental local anesthetic syringe.

2. The solution of claim 1 , wherein said phentolamine mesylate is present at a concentration of from about 0.05 mg/ml to about 0.1 mg/ml.

3. The solution of claim 1 , wherein said container comprises a dose of phentolamine mesylate at or below about 0.25 mg.

4. The solution of claim 3 , wherein said dose is at or below about 0.1 mg.

5. The solution of claim 4 , wherein said dose is about 0.08 mg.

6. The solution of claim 4 , wherein said dose is about 0.032 mg.

7. The solution of claim 1 , wherein said container is a CARPULE.

8. The solution of claim 1 , wherein said container has a volume of between 1.6 and 1.8 ml.

9. The solution of claim 1 , wherein said phentolamine mesylate is at a concentration of about 0.05 mg/ml to about 0.25 mg/ml.

10. The solution of claim 1 , wherein said phentolamine mesylate is at a concentration of about 0.25 mg/ml.

11. The solution of claim 1 , wherein said container comprises a dose of phentolamine mesylate of between about 0.0018 mg to about 0.45 mg.

12. The solution of claim 1 , wherein said dose is between about 0.09 mg to about 0.45 mg.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2019
From: BANK OF MONTREAL
To: SEPTODONT HOLDING
Reel/Frame 050760/0395 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 041476 FRAME 0161. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 9, 2017
From: SEPTODONT HOLDING
To: BANK OF MONTREAL CORPORATE FINANCE
Reel/Frame 041937/0511 →
SECURITY INTEREST Recorded Mar 6, 2017
From: SEPTODONT HOLDING
To: SEPTODONT HOLDING
Reel/Frame 041476/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2011
From: NOVALAR PHARMACEUTICALS, INC.
To: SEPTODONT HOLDING SAS
Reel/Frame 026924/0604 →
Continuity (4)
Continuation 0985275100 · May 11, 2001
Provisional Application 6023585500 · Sep 27, 2000
Provisional Application 6020380000 · May 12, 2000
Related Publication 20020183396A1 · Dec 5, 2002